Cancer & SURVIVEiT News

Financial Advocacy Program For Gynecologic Cancer Patients

September 29, 2020

Cancer doesn’t care what your financial situation is. Thankfully, Carol’s Wish does. Going through cancer treatments is a strenuous time for any cancer patient. It is tough both mentally and…

FDA approves niraparib for first-line maintenance of advanced ovarian cancer

June 2, 2020

FDA approves niraparib for first-line maintenance of advanced ovarian cancer On April 29, 2020, the Food and Drug Administration approved niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients…

FDA approves niraparib for first-line maintenance of advanced ovarian cancer

June 2, 2020

FDA approves niraparib for first-line maintenance of advanced ovarian cancer On April 29, 2020, the Food and Drug Administration approved niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients…

FDA approves niraparib for HRD-positive advanced ovarian cancer

October 30, 2019

FDA approves niraparib for HRD-positive advanced ovarian cancer On October 23, 2019,the Food and Drug Administration approved niraparib (ZEJULA, Tesaro, Inc.) for patients with advanced ovarian, fallopian tube, or primary…

Risk of Developing Ovarian Cancer, Symptoms & New Guidelines For Testing

September 12, 2019

Given the new screening recommendations, and the fact that it’s Ovarian Cancer Awareness Month, we wanted to provide the latest information on BRCA testing, implications, symptoms, risk of developing ovarian…

FDA approves olaparib for first-line maintenance of BRCA-mutated advanced ovarian cancer

January 15, 2019

FDA approves olaparib for first-line maintenance of BRCA-mutated advanced ovarian cancer On December 19, 2018, the Food and Drug Administration approved olaparib (LYNPARZA, AstraZeneca Pharmaceuticals LP) for the maintenance treatment…